A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)
- PMID: 24189082
- PMCID: PMC3822313
- DOI: 10.1136/bmjopen-2013-003573
A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)
Abstract
Objective: To determine the efficacy and safety of eculizumab for patients with atypical haemolytic uraemic syndrome (aHUS), compared with current treatment options.
Design: A systematic review was performed according to the general principles of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. All study designs were included, except case histories.
Participants: All patients diagnosed with aHUS were included; no age restrictions were used.
Interventions: Eculizumab compared with current treatment options.
Identification of studies: 12 databases were searched. Additional searches were performed through the Food and Drug Administration (FDA) and the Electronic Medicines Compendium websites, Google internet searches and contacting clinical experts. Reference lists of relevant articles were checked for additional studies.
Results: 2 small, uncontrolled prospective multinational, multicentre studies and one small uncontrolled multinational, multicentre retrospective study were included. No meta-analyses were performed. Compared with baseline measures, thrombotic microangiopathy event-free status was achieved in 84% of patients in the prospective studies. Adverse events, as documented by enrolling investigators were frequent, with upper-respiratory tract infection affecting a third of patients. No deaths or episodes of meningitis or meningococcal septicaemia occurred in the prospective studies. Results of the study extension phases up to 114 weeks indicate that the benefits of the treatment are sustained.
Conclusions: Eculizumab is clinically effective for the treatment of aHUS. Further research is needed to evaluate eculizumab, ideally using patient-related clinical outcomes. If randomised studies are not feasible, study investigators should ensure that the threat of bias is minimised in future studies of eculizumab with respect to the reporting of patient recruitment and selection.
Similar articles
-
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article.
-
The treatment of atypical hemolytic uremic syndrome with eculizumab in pediatric patients: a systematic review.Pediatr Nephrol. 2023 Jan;38(1):61-75. doi: 10.1007/s00467-022-05683-2. Epub 2022 Jul 21. Pediatr Nephrol. 2023. PMID: 35864223 Review.
-
Eculizumab for paediatric patients with atypical haemolytic uraemic syndrome: full dataset analysis of post-marketing surveillance in Japan.Nephrol Dial Transplant. 2023 Feb 13;38(2):414-424. doi: 10.1093/ndt/gfac150. Nephrol Dial Transplant. 2023. PMID: 35438790 Free PMC article.
-
Practical issues in using eculizumab for children with atypical haemolytic uraemic syndrome in the acute phase: A review of four patients.Nephrology (Carlton). 2018 Jun;23(6):539-545. doi: 10.1111/nep.13054. Nephrology (Carlton). 2018. PMID: 28387984
-
Eculizumab: a review of its use in atypical haemolytic uraemic syndrome.Drugs. 2013 Dec;73(18):2053-66. doi: 10.1007/s40265-013-0147-7. Drugs. 2013. PMID: 24249647 Review.
Cited by
-
Molecular Advances in Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease.Int J Mol Sci. 2023 Mar 15;24(6):5620. doi: 10.3390/ijms24065620. Int J Mol Sci. 2023. PMID: 36982695 Free PMC article. Review.
-
Eculizumab-related drug reaction in a patient with neuromyelitis optica.Clin Case Rep. 2023 Feb 8;11(2):e6835. doi: 10.1002/ccr3.6835. eCollection 2023 Feb. Clin Case Rep. 2023. PMID: 36789316 Free PMC article.
-
Trends and Outcomes of Hospitalizations Due to Hemolytic Uremic Syndrome: A National Perspective.Cureus. 2022 Dec 8;14(12):e32315. doi: 10.7759/cureus.32315. eCollection 2022 Dec. Cureus. 2022. PMID: 36628001 Free PMC article.
-
Kidney diseases.Immunol Rev. 2023 Jan;313(1):239-261. doi: 10.1111/imr.13167. Epub 2022 Nov 12. Immunol Rev. 2023. PMID: 36369988 Free PMC article. Review.
-
Complement System as a New Target for Hematopoietic Stem Cell Transplantation-Related Thrombotic Microangiopathy.Pharmaceuticals (Basel). 2022 Jul 9;15(7):845. doi: 10.3390/ph15070845. Pharmaceuticals (Basel). 2022. PMID: 35890144 Free PMC article. Review.
References
-
- Gasser C, Gautier E, Steck A, et al. Hamolytisch-uramische syndrome: bilateral Nierenrindennekrosen bei akuten erworbenen hamolytischen Anamien. Schweiz Med Wochenschr 1955;85:905. - PubMed
-
- Michael M, Elliott EJ, Craig J, et al. Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials. Am J Kidney Dis 2009;53:259–72 - PubMed
-
- Besbas N, Karpman D, Landau D, et al. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int 2006;70:423–31 - PubMed
-
- Hughes D, Tunnage B, Yeo S. Drugs for exceptionally rare diseases: do they deserve special status for funding? QJM 2005;98:829–36 - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials